MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction

Xiao, Shengjue; Xue, Tongneng; Pan, Qinyuan; Hu, Yue; Wu, Qi; Liu, Qiaozhi; Wang, Xiaotong; Liu, Ailin; Liu, Jie; Zhu, Hong; Zhou, Yufei; Pan, Defeng

doi:10.1155/2021/2923441

Cited by 12 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particularly, this miRNA was higher in NSTEMI than UA patients; moreover, a significant upregulation is reported in the STEMI group compared to the NSTEMI group. Xiao et al [ 64 ] concluded that miR-146a could be used as a new biomarker for adverse prognosis of STEMI; in particular, it may exert its function and its pathogenesis by targeting S100A12, a protein that is involved in the inflammatory response. J. Li et al [ 72 ] analyzed the predictive value of serum miR-203 for acute STEMI, concluding that this miRNA represents a potential new biomarker in the early prediction of STEMI.…”

Section: Resultsmentioning

confidence: 99%

miRNA Dysregulation in Cardiovascular Diseases: Current Opinion and Future Perspectives

Sessa

Salerno

Esposito

et al. 2023

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs), small noncoding RNAs, are post-transcriptional gene regulators that can promote the degradation or decay of coding mRNAs, regulating protein synthesis. Many experimental studies have contributed to clarifying the functions of several miRNAs involved in regulatory processes at the cardiac level, playing a pivotal role in cardiovascular disease (CVD). This review aims to provide an up-to-date overview, with a focus on the past 5 years, of experimental studies on human samples to present a clear background of the latest advances to summarize the current knowledge and future perspectives. SCOPUS and Web of Science were searched using the following keywords: (miRNA or microRNA) AND (cardiovascular diseases); AND (myocardial infarction); AND (heart damage); AND (heart failure), including studies published from 1 January 2018 to 31 December 2022. After an accurate evaluation, 59 articles were included in the present systematic review. While it is clear that miRNAs are powerful gene regulators, all the underlying mechanisms remain unclear. The need for up-to-date data always justifies the enormous amount of scientific work to increasingly highlight their pathways. Given the importance of CVDs, miRNAs could be important both as diagnostic and therapeutic (theranostic) tools. In this context, the discovery of “TheranoMIRNAs” could be decisive in the near future. The definition of well-setout studies is necessary to provide further evidence in this challenging field.

show abstract

Section: Resultsmentioning

confidence: 99%

miRNA Dysregulation in Cardiovascular Diseases: Current Opinion and Future Perspectives

Sessa

Salerno

Esposito

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Present study found that the incidence of MACE in the high-expression group was signi cantly higher than that in the low-expression group, high miR-146a expression level had a poor clinical prognosis than low miR-146a expression level in UA patients, indicating that miR-146a appears to be a reliable biomarker that could evaluate the severity of coronary artery stenosis and predict the prognosis among patients with UA. Xiao et al found that STEMI patients with high expression level of miR-146a had a higher risk of MACE than those with low expression level of miR-146a over 3-year follow-up period [29] . Scărlătescu AI et al found a relationship between the high level of miR-146a-5p and MACE in their research and proved that the expression level of miR-146a-5p is a predictor of MACE during one-year follow-up in STEMI patients [30] .…”

Section: Discussionmentioning

confidence: 99%

Expression level of miR-146a correlates with the coronary lesion severity and clinical prognosis in UA patients

Shi

Wang

Xue

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Objective To investigate whether there is a connection between the plasma expression level of miR-146a and both the severity of coronary lesion and clinical prognosis in patients with unstable angina pectoris (UA). Methods: 100 unstable angina pectoris(UA group) and 100 healthy controls (Control group) were selected to detect the plasma miRNA-146a expression level. To assess the coronary lesion severity in UA patients by Gensini score, analyze the correlation between miR-146a expression level and the degree of coronary artery stenosis in UA patients. The incidence of major cardiovascular adverse events (MACE) were followed up for 48 months after hospitalization and discharge in UA patients. Using the median grouping method to divide the miR-146a expression level in 100 UA patients into high and low expression groups, analyzing the incidence of MACE in patients with different miRNA-146a expression level by the Kaplan-Meier method. Results: The plasma expression level of miR-146a in the UA group was 1.8 times higher than in the control group (Z=6.970, P <0.001), and was correlated with the severity of coronary lesion; the high expression level was associated with a higher Gensini score (P<0.05). Patients with high miR-146a expression level had a significantly higher incidence of MACE compared to those with low miR-146a expression level (Log-rank: P=0.004). Conclusion: The plasma miR-146a expression level of UA patients was correlated with the severity of coronary lesion, and patients with higher miR-146a expression level had a poor clinical prognosis than those with lower expression level.a pectoris (UA group) and 100 healthy controls (Control group) were selected to detect the plasma miRNA-146a expression level. To assess the coronary lesion severity in UA patients by Gensini score, analyze the correlation between miR-146a expression level and the degree of coronary artery stenosis in UA patients. The incidence of major cardiovascular adverse events (MACE) were followed up for 48 months after hospitalization and discharge in UA patients. Using the median grouping

show abstract

“…Supporting these data, higher miR-146a-5p levels were encountered in patients with ACS compared with unstable angina [ 75 , 76 ]. Moreover, Xiao et al found that miR-146a might serve as a marker for MACE in STEMI patients [ 77 ].…”

Section: Discussionmentioning

confidence: 99%

miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction—Added Value over Left Ventricular Myocardial Work Indices

et al. 2022

View full text Add to dashboard Cite

Acute ST elevation myocardial infarction (STEMI) remains a leading cause of morbidity and mortality worldwide despite continuous advances in diagnostic, prognostic and therapeutic methods. Myocardial work (MW) indices and miRNAs have both emerged as potential prognostic markers in acute coronary syndromes in recent years. In this study we aim to assess the prognostic role of myocardial work indices and of a group of miRNAs in young patients with STEMI. We enrolled 50 young patients (<55 years) with STEMI who underwent primary PCI and 10 healthy age-matched controls. We performed standard 2D and 3D echocardiography; we also calculated left ventricular global longitudinal strain (GLS) and the derived myocardial work indices. Using RT-PCR we determined the plasmatic levels of six miRNAs: miR-223-3p, miR-142-3p, miR-146a-5p, miR-125a-5p, miR-486-5p and miR-155-5p. We assessed the occurrence of major adverse cardiac events (MACE) at up to one year after STEMI. Out of 50 patients, 18% experienced MACE at the one-year follow-up. In a Cox univariate logistic regression analysis, myocardial work indices were all significantly associated with MACE. The ROC analysis showed that GWI, GCW and GWE as a group have a better predictive value for MACE than each separately (AUC 0.951, p = 0.000). Patients with higher miRNAs values at baseline (miR-223-3p, miR-142-3p and miR-146a-5p) appear to have a higher probability of developing adverse events at 12 months of follow-up. ROC curves outlined for each variable confirmed their good predictive value (AUC = 0.832, p = 0.002 for miR-223-3p; AUC = 0.732, p = 0.031 for miR-142-3p and AUC = 0.848, p = 0.001 for miR-146a-5p); the group of three miRNAs also proved to have a better predictive value for MACE together than separately (AUC = 0.862). Moreover, adding each of the miRNAs (miR-233, miR-142-3p and miR-146a-5p) or all together over the myocardial work indices in the regression models improved their prognostic value. In conclusion, both myocardial work indices (GWI, GCW and GWE) and three miRNAs (miR-223-3p, miR-142-3p and miR-146a-5p) have the potential to be used as prognostic markers for adverse events after acute myocardial infarction. The combination of miRNAs and MW indices (measured at baseline) rather than each separately has very good predictive value for MACE in young STEMI patients (C-statistic 0.977).

show abstract

MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction

Cited by 12 publications

References 48 publications

miRNA Dysregulation in Cardiovascular Diseases: Current Opinion and Future Perspectives

miRNA Dysregulation in Cardiovascular Diseases: Current Opinion and Future Perspectives

Expression level of miR-146a correlates with the coronary lesion severity and clinical prognosis in UA patients

miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction—Added Value over Left Ventricular Myocardial Work Indices

Contact Info

Product

Resources

About